Further to your request for information dated 13 July 2016 the information requested is below

- **On what date was Vedolizumab (for us in relation to Crohn’s Disease) first added to the Dartford Gravesham & Swanley CCG Formulary?**

  Vedolizumab is a specialist treatment not commissioned for use within primary care so it is not included on NHS Dartford Gravesham and Swanley Clinical Commissioning Group’s (CCG) formulary.

- **What restrictions (if any) does the CCG’s formulary have in place in relation to the number of individual biologic drugs in use/on formulary at any one time for use within Rheumatoid Arthritis?**

  There is no biologic for treatment of rheumatoid arthritis commissioned for use within primary care so therefore it is not on the CCG’s formulary. Prescribing of these drugs is done by hospital specialists.

- **What restrictions (if any) does the CCG’s formulary have in place in relation to the number of individual biologic drugs in use/on formulary at any one time for use within Psoriatic Arthritis?**

  There is no biologic for treatment of psoriatic arthritis commissioned for use within primary care so therefore it is not on the CCG’s formulary. Prescribing of these drugs is done by hospital specialists.
Finally, could you provide a link/attach to your response the latest versions of your patient pathways for Crohn's Disease and Psoriatic Arthritis?

The CCG does not currently have any patient pathways for Crohn’s disease or Psoriatic arthritis.